Venus Remedies Bags Market Authorisation in Serbia For Cancer Drugs

Venus Remedies, based in Chandigarh, announced that it has received marketing authorization from Serbia for two oncology medications gemcitabine and docetaxel. As a result of this, the business has received 511 marketing approvals for its oncology treatments in 66 countries. Oncology pharmaceuticals account for the majority of the Serbian pharmaceutical industry, where Venus Remedies has five marketing approvals, all in the oncology domain, according to the company.

The high prevalence of breast cancer, ovarian cancer, pancreatic cancer, and lung and intestine cancers is a key driver of the global oncology market, which was valued at USD 286.04 billion in 2021 and is expected to reach USD 536.01 billion by 2029 at an 8.2 percent CAGR. Aditi K Chaudhary, President, International Business, Venus Remedies, said, "We have more than 40 marketing authorisations in South Eastern Europe and the Balkan region, including nine for oncology drugs, and we are now banking on the product registrations for gemcitabine and docetaxel from Serbia to pave the way for faster approvals for cancer medicines in other countries in this part of Europe".

The company said it secured a marketing authorisation for gemcitabine from Bosnia a few months ago, followed by marketing approvals for docetaxel from Georgia and two other key cancer drugs from Moldova, as per PTI. "These marketing approvals will not only enable us to expand our operations to new geographies but also reaffirm our commitment to open new avenues for advanced cancer treatment. The marketing authorisation from Serbia is a significant milestone that will help improve access to affordable cancer drugs in the region," Chaudhary said.